Note: Descriptions are shown in the official language in which they were submitted.
HOMOGENEOUS SPECIFIC BINDING ASSAY DEVICE
AND PREFORMED COMPLEX MET}IOD
___
BACKGROUND OF THE INVENTION
1. FIELD OF THE I~VENTION
This invention relates to test devices, their
preparation and their use in determining a ligand in
- a liquid sample based on a specific binding assay,
e.g., immunoassay, principle. In particular, this
invention relates to solid state carrier elements
incorporated with homogeneous specific binding assay
reagents.
Test devices in the form of test strips ancl
similar solid state analytical elements have become
commonplace in the analysis of various types of
samples, particularly biological fluids. Test
strips designed for detecting clinically significant
substances in biological fluids, such as serum and
urine 7 have been advantageous in the diagnosis of
disease.
Test strips of various types have been known and
used for many years in a wide variety of fields, from
the most familiar pH test paper devices to in vitro
diagnostic devices for the detection of various
MS-1168
urine and blood components such as glucose, protein 9
occult blood and so orth (e.g~, as described in V.S.
Patent Nos. 3,164,534; 3,485,587; and 3,012,976).
Reagent compositions found in such conventional test
strips, having limited sensitivity, in-teract with
the constituent or cons~ituen~s ~o be deterrnined by
direct chemical reac~ion and are applied to the
detection of substances that are present in liquid
samples at concentra~ions in the millimolar range or
aboveO
On the other hand, the development of specific
binding assay techniques has provided extremely
useful analytical methods for determining various
organic substances of diagnostic, medical9 environ-
mental and industrial importance which appear inliquid mediums at very low concentrations. Speci-fic
binding assays are based on ~he specific interaction
between the ligand9 i.e.9 the bindable analyte under
determination, and a binding partner therefor. Where
one of the ligand and i~s binding partner is an
antibody and the other is a corresponding hapten or
antigen~ the assay is known as an immunoassay.
In conventional specific binding assay ~echni-
ques, a sample of the liquid medium to be assayed is
combined with ~arious reagent compositions. Such
compositions include a labeled conjugate comprising
a binding component incorpora~ed with a label. The
binding component in the labeled conjugate partici-
pates with other constituents, if any, of the reagent
composition and with the ligand in the medium under
assay. This forms a binding reaction system in which
two species, a bound-species and a free-species, of
the labeled conjugate are formed. In the bound-
species, the binding component of the labeled con-
jugate is bound by a corresponding binding partner,
MS-1168
-- 3
e.g. an antibody, whereas in the free-sE)ecies, tlle
binding component is not so bound. rhe relative
amount or proportion of the labele~ conjugate that
results in the bound-species compare~ to the free-
species is a function of the presence (or amount) ofthe ligand to be detectecl in the tes-t sample.
Where the labeled conjugate in the bound-s~ecies
is essentially indistinguishable in the presence of
the labeled conjugate in the free-species ~y -the
means used to monitor the labe], the bound-species
and the free-species must be physically separated in
order to complete the assay. This type of assay is
referred to in the art as "heterogeneous". ~here the
bound-species and free-species forms of the labeled
conjugate can be distinguished in the presence of
each other, the separation step can be avoided, and
the assay is said to be "homogeneous".
The first discovered type of highly sensitive
speci:Eic binding assay was the radioimmunoassay which
~ employs a radioactive isotope as the label. Such an
assay necessarily must -follow the heterogeneous
format since the monitorable character of the label
is qualitatively unchanged in the free- and bound-
species. Because of the inconvenience and difficulty
of handling radioactive materials and the necessity
of a separation step, homogeneous assay systems have
been devised using materials other than radioisotopes
as the label component, including enzymes~ bacteri-
ophages~ metals and organometallic complexes, co-
enzymes, enzyme substrates, enzyme activators andinhibitors, cycling reactants, organic and inorganic
catalysts, prosthetic groups, chemiluminescent reac-
tants, and fluorescent molecules. Such homogeneous
specific binding assay systems provide a detectable
response, e.g., an electromagnetic radiation signal,
such as chemiluminescence, fluorescence emission, or
MS-1168
s
color change, related to the presence of amount of
the ligand under assay in the liquid sample.
Commercially available test means for performing
specific binding assays are usually in the form of
tes~ kits comprising a packaged combination of con-
tainers holding solutions or rehydra-table composi-
tions of the reagents necessary for carrying out the
assay. To perform the actual assay method, aliquots
of such solu~ions must be manually or instrumen~ally
dispensed into a reaction vessel with the sample. If
manually dispensed7 the assay consequently requires
the time and skill of a technician~ and if instru-
mentally dispensed, the assay consequen~ly requires
the expense and maintenance of dispensing apparatus.
2. B~IEF' DESC~IPTION OF THE PRIOR ART
Solid phase test devices have been applied to
heterogeneous specific binding assays in attempts to
overcome the inconveniences and disadvantages vf the
requisite separation step. A commonly used solid
phase device of this type comprises a nonporous
surface, such as the interior surface of a test tube
or other vessel, to which antibody is affixed or
coated by adsorption or co~alent coupling. U.S.
Patent Nos. 3,826,619; 4,001,583; 4,017,597; and
4,105,410 relate to the use o antibody coated test
tubes in radioimmunoassays. Solid phase tes-t devices
have also been used in heterogeneous enzyme immuno-
assays (U.S. Patent Nos. 4,016,043 and 4,147,752) and
in heterogeneous fluorescent immunoassays ~U.S.
Patent Nos. 4,025,310 and 4,056,724; and British
Patent Spec. No. 1,552,374).
MS-1168
7~
Ihe use of such heterogeneous specific binding
assay test devices is exemplified by the method of
U.S. Patent No. 4,135,884 relating to a so-called
"gamma stick". The test de~ice is incorporated with
the antibody reagent and is brought into contact with
the liquid sample and with the remaining reagents of
the reaction system, principally the labeled con-
jugate. After an incubation period, the solid phase
device is physically removed from the reaction sol-
ution and the label measured either in the solution
or on the test device.
Similar devices where the antibody reagent is
entrapped in a matrix such as a gel or paper web are
described in U.S. Patent Nos. 3,925,017; 3,970,429;
4,138,474; 3,966,897; 3,981,981 and 3,888,629 and in
German OLS 2,241,646. Likewise, devices for use in
heterogeneous specific binding assays wherein the
antibody reagent is fixed to a matrix held in a
1Owthrough column are known (U.S. Patent Nos.
4,0369947; 4,039,652; 4,059,684; 4J153~675; and
4,1669102). The test device is usually incorporated
with less than all of the necessary reagents for
carrying out the assay and is merely a means for
rendering more convenient the necessary separation
step.
Finally, heterogeneous specific binding assay
test devices have been described wherein most or all
of the necessary reagents are incorporated with the
same carrier element, and wherein reagent/sample
contacts and separation of the free- and bound-phases
are accomplished by capillary migrations along the
carrier element (U.S. Patent Nos. 3,641,235; 4,094,647
and 4,168,146). The devices described in such
patents are generally considered dif-ficult to manu-
facture and susceptible to irreproducibility due to
MS-1168
~'2C~ 75
~,
the complex nature of the many chemical and physical
interactions that take place along the carrier ele-
ment during performance of an assay. yet another
approach to a he~erogeneous imm~moassay element is
exemplified by U.S. Serial No. 973,669, published
as European Patent Application 0 013 156.
The application of homogeneous speciic binding
assay reagent systems to solid state test devices
would provide great advantages to the routine user of
such assay systems. The determination of ligands
appea~ing in very low concentrations in liquid sam-
ples would be simplified to the steps of contacting
the device with the sample and measuring, either by
visual observation or by instrumental means, the
resulting signal. Reagents would be provided in a
solid -form, with no need to store, dispense or mix
liqui~ reagents as required when using the prior art
test kits. Solid state devices would also be mucl
more adaptable to automation than the prior art
liquid systems.
British Patent Spec. No. 1,552,607~ commonly
assigned herewith, describes homogeneous specific
binding assay systems employing various novel labels,
including chemiluminescent labels, enzyme substrate
2~ labels and coenzyme labels. At page 23, lines 12 ~t
seq of this patent there is the suggestion to incor-
porate the assay reagents with various carriers
including liquid-holding vessels or insoluble, por-
ous, and preferably absorbent, matrices, fleeces, or
flocksi gels; and the like. This lacks a detailed
teaching of how to apply homogeneous specific binding
assay reagent systems to solid state test devices.
German OLS 2,537,275 describes a homogeneous
specific binding assay reagent system and poses the
possibility of using slides or strips incorporated
MS-1168
~2~
with antibody in performing the assay. In this
suggestion, the labeled conjugate would be first
mixed with the sample and thereafter the an-tibody
incorporated test device contacted with the reaction
mixture. After a suitable incubation time, it is
proposed that the test device would be rinsed with
buffer, dried, and then the signal (Eluorescence)
measured. Thus, this German OLS poses a test device
and assay method much like those already known for
heterogeneous specific binding assay techniques
wherein the test device is immersed in the liquid
reaction mixture, incubated, thereafter removed,
washed, and finally read. Additionally, the proposed
test device does not incorporate all of the binding
assay reagents with the carrier element. Specifi-
cally, only the antibody is proposed to be incor-
porated with the carrier element with the labeled
conjugate being separately added to the sample under
assay prior to contact with the proposed test device.
Canadian patent application No. 381,675 filed on
July 14, 1981 and commonly assigned herewith, discloses
a homogeneous specific binding assay device, a method
for its preparation, and a method for its use in de-
termining a ligand, such as antigen, hapten, or anti-
body, in, or the ligand binding capacity of, a liquid
sample. This includes, for example, a test device
for determining a ligand in or the ligand binding cap-
acity of a liquid sample, comprising (a) reagents for
a homogeneous specific binding assay system which pro-
duces a detectable response that is a function of the
presence of the ligand in or the ligand binding capa-
city of the sample, and (b) a solid carrier member
incorporated with said reagents~
: ' ,`1
SUMMARY OF THE INVENTION
The present invention provides a homogeneous
specific binding assay test de~ice, a method for its
preparation, and a method for its llse in determining
a ligand in a liquid sample. The test device com-
prises (a) reagents for a homogeneous specific
binding assay system which produces a detectable
response that is a function of the presence J in a
qualitative or quantitative sense, of the ligand in
the liquid sample under assay, and (b) a solid car-
rier member incorporated with such reagents. The
carrier member is preferably a matrix which is
absorbent relative to the liquid sample, sucil as web
matrix composed primarily of natural or synthetic
polymer fibers, e.g., paper, or a polymeric film or
gel, such as used in multilayer elements.
Competition between sample ligand and labeled
ligand for binding to a binding partner ~here exe-
mplified by an antibody-"Ab"~ can be summari~ed by
the equation:
ligand
+ Ab:ligand
labeled-ligand +
+ Ab:labeled-ligand
Ab
In the system illustrated aboveg the antibody and the
labeled-ligand are kept separate until the intro-
duction of ~he sample. In contrast, the described
invention makes use of the re~erse reaction and
reequilibration with the ligand as shown by the
equation below:
MS-1168
..~
~Z~Lg'~S
ligand~ Ab:ligand
Ab:labeled-ligand labeled-ligand
where the amount of disp]aced labeled ligand is
related to the sample ligand concentration. The
advantage is that all reagent componen-ts can be
combined in one incorporation medium to provide a
device or element that requires only the addition of
sample to be tested.
In accordance with the invention, the method of
preparing a device for determining a ligand in a
liquid sample comprises forming a complex between a
labeled conjugate, said conjugate comprising a label
component coupled to said ligand or a specific
1~ binding analog thereof 9 and a speci~ic binding partner
for said ligand; and incorporating a carrier with
said complex. For a preferred embodiment, forming
said complex comprises associating said conjugate and
specific binding partner therefor and allowing the
conjugate, the binding partner and the complex to
reach equilibrium. This equilibrium can be such that
subs~antially all o~ said conjugate is complexed. -
In use, the test device is contacted with theliquid sample, e.g., a biological fluid such as serum
or urine, such as by momentarily immersing the reagent
incorporated carrier member in the sample or by dis-
pensing an aliquot of the sample onto a surface of
the carrier member. The detectable response is
thereafter measured, usually after a predetermined
incubation or reaction period, either by observation
of the individual performing the assay or by instru-
ment means. The detectable response is most commonly
an electromagnetic radiation signal, for example,
fluorescence, chemiluminescence, color changes and
spectrophotometric responses.
MS-1168
,
- 10
Preferred homogeneous specific binding assay
systems are those known in the art which involve a
label which participates in an enzymatic reaction.
One such preferred assay system is that wherein the
label is an enzyme prosthetic group and wherein the
extent to which an apoenzyme is able to combine with
such prosthetic group label to form an active holo-
enzyme is dependent on the presence of the ligand or
binding capacity therefor. The holoenzyme can be
measured by its enzymatic activity according to a
wide variety of schemes, including colorimetric
schemes. Another preferred assay system is that
wherein the label is an enzyme substrate and wherein
the extent to which an enzyme is able to act on such
substrate label to produce a detectable product is
dependent on the presence of the ligand or binding
capacity therefor. In such a homogeneous specific
binding assay system~ the detectable product is
preferably fluorescence whereby the detec-table res-
ponse from the test device is measurable by a fluoro-
meter. Also useful as the homogeneous specific
binding assay system is that wherein -the label is an
enzyme and wherein the activity of such enzyme label
is dependent on the presence of the ligand or binding
capacity therefor. In this case also, enzyme activ-
ity can be measured in a wide variety of ways.
BRIEF DESCRIPTION OF THE DR~WINGS
Fig. 1 is a schematic representation of the prin-
ciples of a competitive binding type of homogeneous
immunoassay for a drug.
Fig. 2 shows the reaction sequence for the prepa-
ration of ~-galactosyl-umbelliferone-sisomicin.
Fig. 3 is a graph showing the data obtained in
Example I for gentamicin assay.
Fig. 4 is a graph showing the data obtained in
'~l
~ 9~t~
- lOa -
Example II for tobramycin assay.
Fig. 5 shows the reaction sequence for the prepa
ration of ~-galactosyl-umbelliferone-labeled theophyl-
line conjugates.
Fig. 6 is a graph showing the data obtained in
Example III for theophylline assay.
Fig. 7 shows the reaction se~uence for the prepa-
ration of ~-galactosyl-umbelliferone-labeled carbamaze-
pine conjugates.
Fig. 8 is a graph showing the data obtained in
Example IV for carbamazepine assay.
~2~
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention provides a test device for
use in carrying out homogeneous speci-Eic binding
assays, e.g~, immunoassays, having all of the con-
~enience fea~ures of conventional analytical teststrips and other test elements of similar design. As
in the case of such conventional devices, the present
invention provides a solid carrier, usually a matrix
of one sort or another, incorporated with all of the
reagents necessary to per~orm a given assay whereby
the user has only the task of bringing the test
device into contact wlth the sample -to be tes~ed and
measuring the resulting response. Where the entire
process is automated, an instrument for performing
the same manipulations can have a much simpler design
than one having to deal with conventional liquid
chemistry systems now used for performing homogeneous
specific binding assays.
HOMOGEI~EOVS SPECIFIC BINDING ASSAYS
Reagents for any homogeneous specific binding
assay system may be incorporated in the present test
device. In general, homogeneous specific binding
assay techniques are based on the special interaction
between (1) a conjugate of a binding component and a
label and (2) a binding partner to the binding com-
ponent in the conjugate, whereby a characteristic of
the label is different when the labeled conjugate is
bound by the binding partner compared to when such
conjugate is not so bound. The affected character-
istic of the label may be of any measurable nature~
for instance, a chemical or physical quality of the
MS-ll~
~Z6~ 5
labei. In some cases, the a-ffected characteristic is
a chemical reactivity in a predetermi.ned reaction
which involves the ormation or breaking o:E chemical
bonds, cavalent or noncovalent~ In other cases, the
affected characteristic is a physical characteristic
of the label which can be measured wi~hout chemical
reaction.
In the majority of cases, the present tcst
device will incorporate homogeneous specific binding
assay reagents which interac~ with the ligand in the
sample in an immunochemical manner. That is, tllere
will be an an~igen-antibody or hapten-antibody rela-
tionship.between reagents and/or the ligand or its
binding capacity in the sample. Such assays there-
fore are termed immunoassa.ys and the speci.al inter-
action between the labeled conjugate and its binding
.partner is an immunochemical binding. Thus, in such
instances, the binding component of the labeled
conjugate is an antigen, hapten or antibody ~or a
ragment thereof) and the binding partner is its
corresponding immunochemical binding partner. How-
ever, it is well understood in the art that other
binding interactions between the labeled conjugate
and the binding partner serve as the basis of homo-
geneous specific binding assays, including thebinding interactions between hormones, vitamins,
metabolites, and pharmolocogical agents~ and their
respective receptors and binding substances.
Where the sample is being assayed to determine
the presence or amount of a particular ligand there-
in, the reagents for the homogeneous speciic binding
assay technique comprise, in the usual case, (1) a
labeled conjugate composed of the ligand, or a bind-
ing analog thereof, chemically coupled to the label,
MS-1168
~z~
(2) a binding partner for the ligand, e.g., an anti-
body or fragment thereof, a natural receptor protein,
and the like, and (3? any ancillary reagents nec-
essary for measuring the labeling substance in the
labeled conjugate. A limiting amount of the binding
substance is introduced so that any ligand in the
sample will compete with the labeled conjugate for
binding to the binding partner. The distribution of
the label between the bound-species and the free-
species will therefore determine the magnitude of -the
detectable response from the label, which in turn
will be a function of the presence of the ligand.
~nother scheme for determining a ligand is presented
where the labeled conjugate is composed of a labeled
binding partner of the ligand and upon binding to the
ligand the label is affected in terms of its de-
tectable response.
Several different homogeneous specific binding
assay systems are known in the art, and the following
are examples, without limiting the scope of the
present invention, of some such systems contemplated
for use in the present test device. The following
systems are listed according to the nature of the
label used.
MS-1168
. .
~,9., .
`~ :
~Z~P7~
1. Enzyme prosthetic ~roup 1,~bel s
In this system, where the label is a prosthetic
group of an enzyme, the ability of a catalytically
inactive apoenzyme to combine with the prosthetic
group label to form an active enzyrne (holoenzyme) is
affected by binding of the labeled conjugate with its
binding partner. Resulting holoenzyme activity is
measurable by conventional detectant systems to yield
an ultimately detectable signal. Assay systems of
this type are described in commonly assigned U.S.
Patent No. 4,238,565. A particularly preferred
prosthetic group-labeled assay scheme employs flavin
adenine dinucleotide (FAD) as the label and apo-
glucose oxidase as the apoenzyme. Resu],ting glucose
oxidase activity is measurable by a colorimetric
detectant system comprising glucose, peroxidase, and
an indicator system which produces a color change in
response to hydrogen peroxide.
In such preferred assay scheme, the FAD-labeled
conjugate is preferably of the formula:
NH R-L
<N ~ N
N N J
Riboflavin~ Phos~2 Ribose
wherein Riboflayin-(Phos)2-Ribose represents the
riboflavin-pyrophosphate-ribose res'idue in FAD, R is
a linking group9 and I. is the binding component,
e,g., the ligand or analog thereof.
~IS -11 6 8
3'~i
- 15 -
2. Enzyme subs~rate ~abe~s
In this system~ the label is selected so that
the labeled conjugate is a substrate for an enzyme
and the ability of the enzyme to act on the sub-
strate-labeled conjugate is affected, either in a
positive or negative sense, by binding of the labeled
conjugate with its binding partner. Action of the
enzyme on -the substrate-labeled conjugate produces a
product that is distinguishable in some feature,
usually a chemical or physical feature such as chemi-
cal reactivity in an indicator reac-tion or such as a
photometric character, e.g., fluorescence or light
absorp-tion (color). Assay systems of this type are
described in commonly assigned U.S. Patent No.
4,226,978, copending U.S. application Serial No.
894,836, filed April 10, 1978 (corresponding to
published German OLS 2,618,511) and U.S. Patent No.
4,279V992; and in Ana~. Chem. 48:1933 (1976), Ana~.
Biochem. 77:55 (1977) and c~inO Chem. 23:1402 (1977).
A particularly preferred substrate-labeled assay scheme
employs a labeled conjugate of the structure
C~12H
HO
wherein R is a linking group and L is the binding
component, e.g., the ligand or analog thereof, where-
by the ability of the enzyme ~-galactosidase to
cleave the conjugate yielding a product distinguish-
able by its fluorescence is inhibited by binding of
the conjugate with its binding partner.
'~1
~ '
~.,
~ 2 ~ t~
3. Coenzyme Z~be~s
The labeled conjugate in this system is com-
posed, in its label portion9 by a coenzyme-active
functionality, and tlle ability of such coenzyme label
to participate in an enzymat:ic reaction is affected
by binding of the labelecL conjugate Wit]l its binding
partner. The ra~e of the resulting enzyMatic reac-
tion is measurable by conventional detectant systems
to yield an ultimately detectable signal. Assay
systems of this type are described in commonly as-
signed, copending application Serial No. 8947836,
filed April 10, 1978 (corresponding to published
German OLS 2,618,511); and i31 AnaZ. Bio~hem. 72:271
(1976), AnaZ. Biochem. 72:283 (1976) and Ana~.
Biochem. 76 :95 ~1976).
~. Enzyme moduZator ZabeZs
The labeled conjugate in this system is com-
posed, in its label portion, of an enzyme modulating
functionality such as an enzyme inhibitor or stimu-
lator, and the ability of such modulator label tomodulate the activity of an enzyme is affected by
binding o-f the labeled conjugate with its binding
partner. The rate of the resulting enzymatic reac-
tion is measurable by conventional detectant systems
Z5 to yield an ul-timately detectable signal. Assay
systems of this type are described in commonly owned
U.S. Patent No. 4J134,7g2.
MS-1168
. .
- 17 -
5. Enzyme Z~eZs
In this sys-tem, the labe] is an ellzyme an~ ti~
activity of the en~yme label is a-Efecte(l l)y hi~
of the labeled conjugate with its l~in~lin~ partllel~.
Resulting enzyme ac~ivi-ty is measural~le l)y convell-
tional detectant systelns to yiel~l an Illtimately
detectable signal. ~ssay systelns o~ tllis tyl~c Ire
clescribed in ~I.S. I'a-tcnt No~. ~,817,8.~7 arld 4,()~ 72.
6. Quenchabl~ llul~r~scent la~e1s
The labeled conjugate in this systeln is COIII-
posed, in its label portion, of a Eluorescer h~ho~e
fluorescence is quenched in some measurable degree
when the labeled conjugate is bound by its binding
partner3 usually a protein SUC}I as an antibody. rlle
fluorescent label is measured directly, with its
fluorescence being the detectable signal. Assay
systems of this type are described in U.S Patents
Nos. 4,160,016 and in J. CZin. Path. 30:526 ~1977).
7. ChemicaZZ~-ex~ited fZuorescent ZabeZs
In this system, the label is again a fluorescer~
however, the ability of the fluorescer label to be
chemically excited to an energy state at which it
fluoresces is affected by binding o~ the la~eled
conjugate with its binding partner. Chemical excita-
tion of the label is usually accomplished b~ exposure
o the fluorescer label to a high energy co~pound
-formed in situ. Assay systems of this type are
described in commonly-owned U.S. Patent No. 4,238,195.
~S-1168
8. Doubl,~ ant1body steric hindra~ee ZabeZs
Another assay system is the double antibody
immunoassay system described in U.S. Patent Nos.
3,935,074 and 39998,943 The labeled conjugate
comprises two epitopes, one of whicil participates in
the immunological reaction with the ligand and anti-
ligand antibody and the other of whicll is bindable by
a second antibody, with the restriction that the two
antibodies are hindered from binding to the labeled
conjugate simultaneously. The second epitope can be a
fluorescent substance whose fluorescence is quenched
by the second antibody binding, or may participate in
an ancillary competitive bincling reaction with a
labeled form of the second epitope for binding to the
second antibody. Various detectant systems are
possible in such a system as described in the afore-
mentioned patents. Related assay systems are des-
cribed in U.S. Patent Nos. 4,130,462 and 4,161,515
and in British Patent Spec. No. 1,560,852.
9. Energy trans~er labe7~s
In this system, the label is one member of an
energy transfer donor acceptor pair and the binding
partner is conjugated with the other of such pair.
Thus, when the labeied conjugate is bound by binding
partner, the energy expression of the donor component
of the pair is altered by transferance to the ac-
ceptor component. Usually, the donor is a fluorescer
and the acceptor is a quencher therefor, which
quencher may or may not be a fluorescer as well. In
MS~ 8
~LZ63~L~'7~
- 19 -
such embodiment, the detectable signal is fluores-
cence, but other detectan-t systems are possible also.
Such assay systems are described in U.S. Patents Nos.
3,996,345; 4,1~4,384; and 4,199,559 and in British
Patent Spec. No. 2,018,424.
10. Ot~2eY~ Zc~beZs
Other homogeneous specific binding assay systems
described in the art which can be used in the present
invention include the use of such labels as:
(a) nonenzymic catalysts, such as electron
transfer agents (see U.S. Patent No.
4,160,645);
(b) nonenzymic chemiluminescers (see commonly
owned, copending application Serial No.
894,836 which corresponds to published
German OLS 2,618,511);
(c) "channeling" labels (see British Patent
Spec. No. 2,018,986);
(d) "particle" labels (see British Patent Spec.
No. 2,019,562); and
(e) labeled liposome particles (see U.S. Patent
No. 4,193,983).
I,I GA ~D
The present assay may be applied to the detection
of any ligand for which there is a specific binding
partner. The ligand usually is a peptide, polypep-
tide, protein, carbohydrate, glycoprotein, steroid,
nucleic acid, polynucleic acid sequence or other
organic molecule for which a specific binding partner
s
::
3'7S
- 20 -
exists in biological systems or can be syn-thesized.
The ligand, in unctional terms, is us~lally selected
from the group comprising antigens and antibodies
-thereto; haptens and an~ibodies thereto; a~d hor-
mones, vitamins, metabo:lites and pharm~cologicalagents, and their recep~ors and binding substances.
Usually, the ligand is an immunologically-active
polypeptide or protein of molecular weight between
l,000 and 1~,0009000, such as an antibody or anti-
genic polypeptide or protein, or a hapten of mole-
cular -weigh-t between 100 and 1,500.
Representative polypepti.de ligands are angio-
tensin I and II, C-peptide, oxytocin, ~asopressin,
neurophysin, gastrin7 secretin, bradykinin, and
glucagon
Representative protein ligands include the
classes of protamines 7 mucoproteins, glycoproteins,
globulins, albumins, scleroproteins, phosphoproteins,
histones, lipoproteins, chromoproteins, and nucleo-
proteins Examples of specific proteins are pre-
albumin~ al-lipoprotein, interferon9 human serum
albumin3 c~l-glycoprotein, transcortin, thyroxine
binding globulin, haptoglobin, hemoglobin, myglobin,
ceruloplasmin, c~2-lipoprotein, c~2-macroglobulin, ~-
lipoprotein~ erythropoietin, transferrin, homopexin,fibrinogen, the immunoglobulins such as IgG, IgM,
IgA, IgD, and IgE, and their fragments9 e.g., Fc and
Fab, complement factors, prolactin, bloocl clotting
factors such as fibrinogen, thrombin and so forth,
insulin, melanotropin, somatotropin, thyrotropin,
follicle stimulating hormone, leutinizing hormone,
gonadotropinl thyroid stimulating hormone, placental
lactogen, intrinsic factor, transcobalami.n, serum
MS-1168
. ,.
3'~
enzymes such as alkalirle p}losphatase, ~Lactic dehydro-
geanse, amylase, lipase, phosphatases, cholinesterase,
glutamic oxaloacetic transaminase, glutamic pyruvic
transaminase, and uropepsin, endorphins, enkephalins,
protamine, tissue antigens, bacterial antigens, and
viral antigens such as heptatitis associated antigens
(e.g., HBsAg, HBCAg and IIBeAg).
Representative hapten ligands include the gen-
eral classes of drugs, metabolites~ hormones, vi-ta-
mins, and the like organic compounds. ~laptenichormones include thyroxine and triiodothyronine.
Vitamins include vitamins A, B, e.g., B12, C, D, E
and K, folic acid and thiamine. Drugs include anti-
biotics such as aminoglycosides, e.g., gen-tamicin,
tobramycin, amikacin, sisomicin, kanamycin, and
netilimicin, penicillin, tetracycline, terramycin,
chloromycetin, and actinomyce~in; nucleosides and
nucleotides such as adenosine diphosphate (ADP),
adenosine triphosphate ~ATP), flavin mononucleotide
(FMN), nicotinamide adenine dinucleotide ~NAD) and
its phosphate derivative ~NADP~, thymidine, guanosine
and adenosine; prosta~landins; steroids such as the
estrogens, e.g., estriol and estradiol, sterogens,
androgens, digoxin, digitoxin, and adrenocortical
steroids; and others such as phenobarbital, pheny-
toin, primidone, ethosuximide, carbamazepine, val-
proate, theophylline, caffeine, propranol~l, pro-
cainamide, quinidine, amitryptiline, cortisol,
desipramine, disopyramide, doxepine, doxorubicin,
nortryptiline, methotrexate, imipramine, lidocaine,
procainamide, N-acetylprocainamide, the amphetamines,
the ca~echolamines, and the antihistamines.
MS-116~
"
7~
- 22 -
The liquid medium to be assayed can be a nat-
urally occurring or artifically formed liquid sus-
pec~ed to contain the ligand, and usually is a bio-
logical -fluid or a dilution thereof. Biological
fluids that can be assayed include serum, plas]na,
urine, saliva, and amniotic and cerebrospina] fluids.
CAF~RIER MEMBI~R
The carrier member of the present invention can
take on a multitude o forms, and is therefore in-
~ended as being broad in context. It can be mono- or
multi-phasic, comprising one or more appropriate
materials or mediums of similar or different absorp-
tive or other physical characteristics. It can be
hydrophobic or hydrophilic, bibulous or nonporous.
In its most efficient embodiment the carrier member
can be carefully tailored to suit the characteristics
of the particular homogeneous specific binding assay
system to be employed.
Thus, as used herein, the term "carrier member"
can comprise any substance, matrix, or sur-face cap-
able of being incorporated with specific binding
assay reagents. It can take on many known forms such
as those utilized for chemical and enzymatic reagent
strips for solution analysis. For example, U.S.
Patent No. 3~846,247 teaches the use o felt, porous
ceramic strips, and woven or matted glass fibers. As
substitutes for paper, U.S. Patent No. 3,552,928
teaches the use of wood sticks, cloth, sponge mater-
ial, and argillaceous substances. The use of syn-
the~ic resin fleeces and glass fiber felts in place
of papers is suggested in British Patent No. 1,369,139.
Another British Patent, No. 1,349 7 623~ suggests the
MS-1168
.
.
.
, . . . .
. ,
~2~ 75
- 23 -
use of a ligh~-permeable meshwork of thin filaments
as a cover for an underlying paper carrier element.
This reference also suggests impregnating -the paper
with part of a reagent system and impregnating the
meshwork with other potentially incompatible chemical
or enzymatic reagents. French Patent No. 29170,3~7
teaches the use of carrier members having greater
than 50% polyamide fibers therein. Another approach
to carrier members is disclosed in U.S. Patent No.
4,046,513 wherein the concept of printing reagents
onto a suitable carrier is employed. U.S. Patent No.
4,046,514 discloses the in~erwea~ing or knitting of
filaments bearing reagen~s in a reactant system. All
such carrier member concepts can be employed in the
present invention, as can others. Preferably the
carrier member comprises a bibulous material, such as
filter paper, whereby a solution or suspension of the
reagents of the speci~ic binding assay system is used
to impregnate the carriar member. It can also com-
prise a system which physically entraps these ingre-
dients, such as in polymeric microcapsules, which
then rupture upon contact with the test sample. It
can comprise a system wherein the ingredients are
homogeneously combined with the carrier member in a
fluid or semi-fluid state, which later hardens or
sets, thereby entrapping tha ingredients.
Whichever material is chosen for the carrier
member, whether it be porous to permit incorporation
of ingredients such as thorough saturation with a
solution containing them~ whether it be nonporous
such as for use in printed application of reagents or
to support a continuous coating~ whe~her it be woven
or knitted, whatever its composition or canfigura-
tion, its selection will in any event be dictated by
anticipated use and by the reagent system.
MS-1168
C~7S
- 2~ -
~ or example, the system is prepared by first
preincubating the antibocly and the conjugate for the
detection of a specific ligand. rhe ratio o-f avail-
able antibody binding sites to available conjugate is
preferably 1:1. The complex i5 allow~d to preform,
usually requiring a duration not longer than about
fifteen minutes. At the end of this period, any ad-
ditional reagents which might be necessary such as an
enzyme (e.g., ~-galactosidase), are added to the
solution. For a quenching system the introduction of
additional reagents would not be necessary. The
solution is then applied to a carrier and this is
allowed to set. This is then cut into the appropriate
geometry to provide analytical elements.
~here the carrier member comprises multiple
layers, e.g , paper or other fibrous material, such
layers may be maintained in laminar relationship by
adhesives which permit fluid passage between layers.
In preparing integral analytical elemen~s using film
formers, ~he layer~s) can be preformed separately and
laminated to form the overall element. The material
of the film layer(s) can be a composition comprising
a plas~icizer and a polymer suitable to impart dimen-
sional stability. Layers prepared in such a manner
are typically coated from solution or dispersion onto
a surface from which the dried layer can be physically
stripped. However, a convenient method which can
avoid problems o~ multiple stripping and lamination
steps is to coat an initial layer on a stripping
surface or a support, as desired, and theraEter to
coat successive layers directly on those coated
previously. Such coating can be accomplished by
hand, using a blade coating device, or by machine,
using techniques such as dip or bead coating. If
machine coating techniques are used, it is often
MS-~16~
. ~
:
.
- 25 -
possible to coat adjacent layers simultaneously using
hopper coating techniques well known in ~he pre-
paration of light sensitive photugraphic films and
papers.
Blu-;h polymer layers can be used as the -~ilm
layer material. The film is formed on a substrate by
dissolving a polymer in a mixture of ~wo liquids, one
of which is of a lower boiling point and is a good
solvent for the polymer and the other of which is of
a higher boiling point and ls a nonsolvent or at
least a poor solvent for the polymer. SUC}1 a polymer
solution is then coated on the substrate, and dried
under controlled conditions. The lower boiling
solvent evaporates more readily and the coating
becomes enriched in the liquid which is a poor sol-
~ent or nonsolvent. As evaporation proceeds, under
proper conditions, the polymer forms as a porous
layer. Many different polymers can be used9 singly
- or in combination, for preparing porous blush polymer
layers for use in this invention. Typical examples
include polycarbonates, polyamides, polyurethanes and
cellulose esters s~ch as cellulose acetate. For
layers such as those containing a labeled conjugate
or other reagent, a coating solution or dispersion
including the matrix and incorporated active mat-
erials can be prepared, coated as discussed herein
and dried to form a dimensionally stable layer.
The thickness of any layer and its degree of
permeability are widely variable and depend on actual
usage. Dry thickness of from about 5 microns to lO0
microns have been convenient, although more widely
varying thickness may be preferable in certain cir-
cumstances. For example~ if comparatively large
` amounts of interacti~e material, e.g., polymeric
materials like enzymes, are required, it may be
desirable to prepare slightly thicker layers.
MS-1168
9~7~
- 26 -
Tt can also be clesirablc to inclu~e within a
carrier member one or more reflective layers, oT~tion-
ally absorptive to detecting radiation, such as to
facilitate signal detection by reflection radiometry,
e.g.~ reflection photometry or a similar technique.
Such reflector can be provided by one of the above-
described layers or it can be provided by an ad-
ditional layer that may not have an ad~itional func-
tion within the element. Reflective pigments, such
as -titanium dioxide and barium sulfate, can be usecL
to advantage in a reflccting layer. Blush polymers
can also constitute a suitable reElecting material.
In one preferred aspect, blush polymer layers can
also incorporate a pigment to enhance reflectivity or
other functions. The amount of pigment that can be
included in a layer together with a blush polymer is
highly variable, and amounts oE from about 1 to about
10 parts by weight of pigment per part by weight of
blush polymer are preferred, with from about 3 -to
abou~ 6 parts pigment per part of blush polymer being
most preferred.
It can be advantageous to incorporate one or
more surfactant materials, such as anionic and non-
ionic surfactant materials, in the layers of the
carrier member. They can, for example, enhance
coatability of laye~ formulations and enhance the
extent and range of wetting in layers that are not
easily wetted by liquid samples in the absence of an
aid SUC}l as a surfactant. In layers of the carrier
it can also be desirable to lnclude materials that
can render nonactive in the analysis of choice, by
chemical reaction or oth~rwise, materials potentially
deleterious to such analysis.
~s mentioned previously herein, the integral
analytical elements can be selE-supporting or coated
MS-1168
.
'75
on a support. The support can be opa~ue or trans-
parent to light or o-ther energy. A support of choice
for any particular carrier member will be compatible
with the intended mode o~ signal de-tection. Pre-
ferred supports include transparent support materialscapable o transmit-ting electromagnetic radiation of
a wavelength within thc region between abou-t 20~ nano-
meters (nm) and about 900 nm. The support need not,
of course, transmit over the entire 200-900 nm
region, although or fluorometric detection of analy-
tical results through the suppor~ it is desirable for
the support to transmit over a wider band or, alter-
natively, to transmit at the absorp-tion and emission
spectra of the fluorescent materials used for de-
tection. It may also be desirable to have a supportthat transmits one or more narrow wavelength bands
and is opaque to adjacent wavelength bands. This
could be accomplished, for example, by impregnating
or coating the support with one or more colorants
having suitable absorption characteristics.
DETECTABLE RESPONSE
As previously noted, many of the recently de-
vised homogeneous speci-fic binding assay systems
provide~ or can be readily adapted to provide, a
Z5 detectable response such as a color change, chem-
iluminescence, or fluorescence related to the pre-
sence o-r amount of the ligand under assay in the
liquid sample.
The term "detectable species", and similar terms
as used herein, refer to atoms, chemical groups
(i.e., a portion of a molecule~ or chemical compounds
that are themselves directly or indirectly detectable
and the term "detectable response", and similar terms
MS-1168
; ~ .
`7~
- 28 -
as used herein~ reCer to the detectable mclnirestation
of tlle presence of such species~ Examples are elec-
tromagnetic radiation signals such as fluorescence,
phosphorescense, chemiluminescence, a change in light
absorption, or reflectance in the visible spectrum
thereby producing a visible color change~ a change in
light absorption or reflec~ance outside the visible
range such as the ultraviole~ or inraled. As will
be apparent to one skilled in the art of immuno-
assays, the phrase "detectable response", as usedherein, is intended in its broadest sense. In ad-
clition to electromagne~ic radiations signals the term
"detectable response" is also meant to include any
observable change in a system parameter 3 such as a
change in or appearance of a reactant, observable
precipitation of any component in the -test sample or
a change in any other parameter, whether it be in the
immunoassay system or the test sample. Such other
detectable responses include electrochemical res-
ponses and colorimetric responses. Moreover, thedetectable response is one which can be observed
through the senses directly or by use of ancillary
detection means, such as a spectrophotometer, ultra-
violet light-sensing equipment, -fluorometer, spectro-
fluorometer, pH meter and other sensing means. De-
sirably, such detectability can be conveniently
imparted to the full amount of detectable species
wi-thout affecting the amoun~ of diffusible product
resulting from the analyte interactions which are the
basis of the intended analysis.
After the analytical result is obtained as a
detectable change, it is measured, usually by passing
the test element through a zone in which suitable
apparatus for re-flection, transmission or fluores-
cence photome~ry is provided. Such apparatus serves
~S-11~8
3L9~i
29
to direc-t a beam of ener~)~, such as ].i~ht9 through,
in one embodiment, the support. Ihe ligh-t is then
reflected f:rom the element back to a detecting means
or passes -through the element to a detector in the
case of transmission detection. In a preferred mode,
the analytical result is detected in a regi.on of the
element totally within the region in which such
result is produced. IJse of refl~c~ion spectrophoto-
me~ry can be advantageous in some situa~ions as it
eEfectively avoids optical inter-ference from any
residues, such as blood cells or urine sediment,
which have been left on or in the layers o~ the
element or from atypical urine colors. Conventional
techniques of fluorescence spec-trophotometry can also
be employed if desired. Futhermore, transmission
techniques can be used to de~ec~ and quanti~y the
incI:icating reaction products by reacting a flow of
racliant energy, for example~ ultraviolet, ~isible or
infrared radiation at one surface of the element and
measuring the output of that energy from the opposing
surface of the element. Generally, electromagnetic
radiation in the range of ~rom about 200 to about 900
nm has been found useful for such meaSUrelllentS~
although any radiation to which the element is per-
meable and which is capable of quantifying the pro-
duct produced in the element can be used. Various
calibration techniques can be used ~o provide a
control for the analysis. As one example, a sample
of a standard solution of the ligand under assay can
be applied adjacent to the area where the drop of
sample is placed in order to permit the use of dif-
ferential measurements in the analysis.
MS-1168
g~s
- 3~ -
EXAMPLES
The following examples describe experiments
which were performed in developing the present in-
vention. While they illustrate preferred embodiments,
they are in no way to be interpreted as limiting the
scope of the invention.
EXAMPLES l-2
Aminog~yeoside Antibiotic Assays
In aminoglycoside antibiotic assays according to
the present invention a labeled conjuga-te is used
wherein the binding component is the antibio-tic under
assay or a binding analog thereof. A schematic
representation of the principles of a competitive
binding type of homogeneous i~munoassay for a drug is
shown in Pigure 1 of the drawings. In assays where
antibody is used as the binding partner it has been
found that other aminoglycoside antibiotics can
cross-react with the antibody for the an-tibiotic
under assay. Thus such other antibiotics qualify as
binding analogs and may be used to form the labeled
conjugate. Further, the antibody ~ualifies as rea-
gent for use in assays for the cross-reacting anti-
biotic. For example, in an assay for gentamicin it
has been found that with appropriate antiserum ~he
binding component in the labeled conjugate can be
gen~amicin itself or sisomicin whic}l cross-reacts.
Thus, gentamicin antlserum and a labeled sisomicin
conjugate could be used in an assay for gentamicin.
Specificity problems are not encounterecl in clinical
situations because it would !~e known what antibiotic
MS-1168
~2691~
was admirlistered and only one aminoglycoside ant;-
bio-tic is aclministered at a time.
The ~-galactosyl-umbelliferone-laheled conjugates
formed are of the ormula:
CH2OH
\ ~ - L
_ ,~
wherein R is a linking grou~ as described herein-
before terminating in an amino-linking group, pre-
ferably carbonyl; L is an aminoglycoside antibiotic
coupled by a covalent bond to the linking group R
through a primary amino group therein; and n equals 1
to the total number of primary amino groups in the
selected antibiotic, inclusive.
E~camp~e 1 - Centami~in Assay
Conjuga.te Preparation
The reaction sequence for the preparation of the
glycone-dye-drug conjugate is given in Pigure 2 in
the drawings. 3-carboethoxy-7-hydroxycoumarin (II)
was prepared by a Knoevenagel condensation of 2,4-
dihydroxybenzaldehyde (Aldrich Chemical Co., Mi.l-
wa~kee, Wisconsin, IJSA) with diethylmalonate in
~IS-ll(;~
~2~'7~
32 -
acetic acid9 benzene, and piperidine as clescribed in
J. ~m. Chem. So~. 63:3452 (1971). Ihe potassium salt
of 7-~-galactosylcoumarin-3-carboxylic acid (III)
was prepared by the reaction of 3-carboet}loxy-7-
hydroxycoumarin (Il) and 2,3~,6-tetraacetyl-~-1)-
galactosyl bromide (~ Sigma Chemical Co., St. Touis,
Missouri, USA) as described by l.eaback ~or the pre-
paration of methylumbel~iferyl-~- n- galactoside in
C~n. Chim. A~-ta 12: 647 (19~5). Ihe potassium salt
of this compound was purified by chroma-tography on
silica gel-60 (E. ~lerck, St. Louis, r~issouri, USA)
with a gradient of Yl-butanol/methanol/wa~er (~/2/1 by
volume) and methanol/water (1/6). After recrystal-
lization from acetone-water, the correc-ted melting
pOiIlt of the product was 258-263C (decomp.).
Analysis: Calcu1ated for C16lll5(~
l-l, 3.73; K, ~.62.
Found: C, 47.30; ll~ 3.74; K, 9.34.
[~3D = ~77 4 (c 1.0, 1l20),
NMR Spectrum (D20): ~ 8.2 (s, 111),
7.6 ~m, lH), 7.0 ~m, 211), 5.1 (s,
lH)~ and 4.0 ~m, 6H).
Infrared Spectrum (KBr): 1705 cm 1
~carbonyl), 1620 cm 1 ~C=C).
~-Galactosyl-umbelliferone-sisomicin (IV) was
prepared by mixing 50 milligrams (mg) (117 ~mol) of the
potassium salt of 7-~-galactosylcoumarin-3-carboxylic
acid ~III) with 171 mg o sisomicin sulfate (223 ~mol
of sisomicin free base, Schering Corp., Bloomfield~
New Jersey, USA) in 2 ml of water. l]-e pl~ was ad-
justed to 3.8 by dropwise addition o-f 1 molar hyclro-
chloric acid. The solution was cooled in an ice bath
and 30 mg ~150 ~mol) of 1-ethyl-3-~3-dimethylamino-
propyl)-carbodiimide hydrochloride (Pierce Chemical
Co., Rockford, Illinois, USA) was added. After 2
,
'75
- 33 -
hours the mix~ure was chromatograp]~e~l at 25~C on a
2.5 x 50 centimeter ~cm) column of CM-~cphadcx ~-25
(Pharmacia Laboratories, Inc., Piscataway, !~ew Jersey,
USA) 5.8 ml fractions were collec~ed9 and their
absorbance was monitored at 345 nanometers (nm). The
column was washed with 200 ml of 50 mmol/liter ammon-
ium formate to elute unreacted 7-~-galactosylcou-
marin-3-carboxylic acid (I~I)o A linear gradient
formed with 400 ml of 50 r~nol/liter and 400 ml of
1.8 mol/liter ammonium ormate, was applied to the
column. A peak of ma~erial absorbing at 345 nm
eluted at approximately 1.4 mol/liter ammonium for-
ma~e. After the gradient, the column was washed with
600 ml of 1.8 mol~liter ammonium formate. Three 345
nm absorbing peaks were eluted in this wash. Eluted
unreac~ed sisomicin was well separated from the last
345 nm absorbing peak.
The carbodiimide-activated TeaCtion leads to the
formation of amide bonds between the carboxylic acid
of ~-~7-(3-carboxy-coumarinoxy)~-galactoside and ~he
primary amino groups of sisomicin. The major peak of
~-galactosyl-umbelliferone-sisomicin (the last 345 nm
absorbing peak) was used in the present studies.
Ammonium formate was remo~ed by lyophilization. Be-
cause the absorptivity of isolated labeled conjugateis currently unknown, the relative concentra~ion is
p e t in e ms of A345 units~ One A345 unit is
the quanti~y of material contained in 1 ml of a
solution that has an absorbance of 1.0 at 345 nm when
measured with a 1 cm light path.
Antisera Preparation
Antiserum to gentamicin was prepared as des-
cribed in Nature New B~oZ. 239: 214 (1972).
MS-1168
- ~ I * Trade Mark
t5
- 3 4 -
Element Preparation
A conjugate solution prepaled in 5.0 mmol/liter
sodium formate (pH 3.5) contained 67.8 micromolar
(~m) of the ~-galactosyl-umbelliferone-sisomicin
conjugate (prepared as referenced above). An anti-
serum solution, preparecl of 10 microliters ~L) of
the antiserum (prepared as referenced above~ 3.6 ~L
of water and 4 ~L of a 0.5 molar N,N-bis-(2-hydro-
xyethyl)-glycine (Bicine) buffer (p~ 8.2, Nutritional
Biochemicals Corp., Cleveland~ Ohio, USA), was com-
bined with 1.9 ~L of the conjugate solution. This
combined solution of conjugate and antiserum was
incubated at 25C for approximately fifteen (15)
minutesO The result was a solution of antibody bound
conjugate
To this solution was added ~.5 ~L of a reagent,
prepared in 50 mmol/liter Bicine buffer which con-
tained 132.7 Units (U)/ml of ~-galactosidase (25 n~
Protein/ml, Escherichia co~i - derived enzyme, Grade
IV, Sigma Chemical Co., St. Louis, Missouri, USA).
One unit (U) of the enzyme was defined as that amount
which hydrolyzed 1.0 ~mole of o-nitrophenyl-~-D-
galactoside per minute of pH 7.2 at 37C. The
enzyme preparation used had a specific ac~ivity of
745 U per milligram of protein. The complete sol-
ution so prepared was then incubated at 25~C for
fifteen (15) minutes.
Carriers comprised of l x 1 cm pieces of Whatman
31 ET filter paper (Whatman, Inc., Clifton9 New
Jersey) were laminated onto silver Mylar and mounted
by double-faced adhesive tape on 8.3 x 1 cm poly-
styrene supports. The above prepared solutions were
MS- 1168
* Trade Mark
s
then pipetted onto the carrier surface opposite the
silver Mylar. These were dried in a convection oven
at 50C for 15 minutes.
Final reagent contents per gentamicin immuno-
assay element were as fo:Llows:
COMPONENT CONTENT
. .
Volume Antisera 10 ~I,
Conjugate ~-gal-umb-sisomicin
Quantity :l30.0 picomoles
~uffer (bicine) 2.0 micromoles
~-galactosidase 0.065 Units
Sodium formate 9.5 nanomoles
Analytical Procedure
The analytical elements which had been prepared
and fixed to supports as described above were placed
in a chamber suitable for maintaining a constant
humidity. Prior to closing the chamber, 70 ~L ali-
quots of drug were pipetted onto -the exposed surface
of the respective analytical elements.
The fluorescence generated at room temperature
at the end of 15 minutes was measured in a fluoro-
meter equipped with a mechanical holder suitable for
horizontally positioning the analytical element. The
fluorometer had been adjusted to provide an excita-
tion light source at 405 nm, which struck the surface
at 9Q and to detect light emitted at a wavelength o
450 nm. A front ace measurement of fluorescence was
made at a 90 angle from the pad.
The concentration ranges assayed were as follows:
I~IS~
. ., ~ ~, . ,.~
~2~ 7~
- 36 -
RANGF. GENTAMICIN
___
Therapeutic Range 1-lO ~g/ml
Dose Response Range 0-2.0 ~g/ml
Checked
The dose response range checked covers the thera-
peutic range since solutions containing up to 10 ~g/ml
were checked after 1:5 dilution in distilled wa~er.
Results
The data obtained by the above-described procedure
is graphically illustrated by Figure 3. l`he ordinate
units are expressed in terms of millivolts (mv). A
millivolt is one thousanth of a volt.
Conclusion
The resultant data show that integral analytical
elements, prepared according to the invention provide
quantitatively detectable signals which are res-
ponsive to the concentration ranges of the gentamicin
present, Increasing conc0ntrations of gentamicin
- results in a drug dependent increase in fluorescence
of the respecti~e analytical elements. The techni-
ques used in the experiment described have made it
possible for all components to be incorporated into a
single solution which is incorporated with a carrier
to form a single element.
MS-116g
~ZC~3~75
- 37
E~ampZe II - 7'o~ramy~in As~ay
Conjugate Preparation
rhe reaction sequence and methodology for the
preparation of the label~d tobramycin conjugate were
basically those of Example I.
With 55 mg ~135 ~mol) of the potassium salt of
7-~-galactosylcoumarin-3-carboxylic acid was mixed
150 mg (220 ~mol~ of tobramycin (Eli Lilly ~1 Co.
Indianapolis, Indiana9 USA) in 1.5 ml of distilled
-water The pl-l was adjusted to 3.65 by the dropwise
addition of lN hydrochloric acid and the resulting
solution cooled in an ice bath. To initiate the
coupling reaction~ 30 mg (160 ~mol) of 1-ethyl-3(3-
dimethylaminopropyl) carbodiimide hydrochloride were
added. After overnight incubation of 4C, two drops
of lN sodium h~droxide were added to give a p~l of
6.1.
The product was purified by chromatography on
carboxymethyl Sephadex gel (Pharmacia Laboratories~
Inc.) with ammonium formate as eluant. After an
initial wash with 0.05M ammonium formate to remove
unreacted galactoside, l.SM ammonium formate was used
to elute conjugated products. Five peaks of material
absorbing at 345 nm were eluted, with khe third peak
being selected for use in this study.
Antis`era Preparation
Antiserum to tobramycin was prepared as des-
cribed in Na~ure New BioZ. 239: 214 (1972).
~IS-ll 68
S
- 38 -
~lement Pr'epar'ation
Preparation of the analytical element was as
described in Example 1 with the exception that ~hc
con;jugate and antiserum used were those pre~ared as
described in ~his Example.
Final reagent contents per tobramycin immuno-
assay element were as follows:
COMPONENT CON'rENT
Volume Antisera 10 ~L
Conjugate ~-gal-umb-tobramycin
Quantity 100.0 picomoles
Bu-ffer (bicine) 2.0 micromoles
~-galactosidase 0.065 Units
Sodium formate 1.7 nanomoles
Analyti'cal Pr~o _dure
The procedure followed in performing the assays
reported by this Example were identical with those
described in Example 1.
The concentration ranges assayed were as follows:
RANGE TOBRAMYCIN
Therapeutic Range 1-10 ~g/ml
Dose Response Range 0-0.6 ~g/ml
Checked
The dose response range checked inclIldes the thera-
'5 peutic range after a 1:20 ~ilution.
MS-1168
~2~g~s
39 -
Results
The data obtained by the above-descrihed procedure
is graphically illustrated by Figure 4. The ordinate
units are expressed in terms of electrical output.
Conclllsion
*he resultant data sllow that integral analytical
elements, prepared according to the in~ention, pro-
vicle quantitatively detectable signals which are
responsive to the concentration rang~es of the to~ra-
mycin present, Increasing concentrations of to~ra-
mycin results in a drug dependent increase in -fluores-
cence of the respective analytical elements. The
techniques used in the experiment described have made
it possible for all components to be incorporated
into a single solution which is incorporated with a
carrier to form a single element.
E~camp Z e I I I - The o p hy Z ~ i n e A 6 s ay
Theophylline [1,3-dimethylxanthine, cf. The
Me~ck Index, 9th ed., p. 1196 ~1976)] is a drug
useful in the management of asthma. In most pa~ients,
the therapeutic range o serum concentratlon lies
between 10 and 20 ~g/ml whereas toxicity almost
invariably appears at blood levels over 35 llg/ml.
Conjugate Prepara`tion
~-galactosyl-umbelliferone-labeled theophylline
conjugates are prepared according ~o the reaction
MS-1l6~
--
~2~ '7~
- 40 -
scheme shown in Figure 5. This synthetic route is
exemplified by the following method of preparing 8-
[3-(7-~-galactosylcoumarin-3-carboxamido)propyl]theo-
phylline (VIII), n = 3.
8-(3-Aminopr~yl)theophyllirle ~II)
._ _
A mixture of 2.66 ~ (0.01 mol) of 8-(3-carboxy-
propyl)theophylline (V) [Cook et a~ Res. Commun.
Chem. Path. PharmaeoZ. 13(3) :4-97-505 (1976)], 20 ml
of chloroform, and 3 ml of concentrated sulfuric acid
-was stirred at 50C under an argon atmosphere. To
this was added 1.3 g of solid sodium azide portion-
wise over a 90 minute period [cf. OYgani~ Rea~tions
47:28 (1967)]. The reaction was cooled and the
solvent removed under reduced pressure. The residue
was combined with enough sodium bicarbonate solution
to bring the pH to 7.5O Ten grams of celite (Fisher
Scientific Co., Pittsburgh~ Pennsylvania) was added
and the water evaporated. The impregna-ted celite was
placed atop a column of 200 g of silica gel (E. Merck
Co., Darmstadt, West Germany) made up in 9:1 (v:v)
ethanol - 1 molar aqueous triethylammonium bicar-
bonate. The column was eluted with this solvent and
15 ml fractions were collected. Fractions 171 to 225
wcre combined and evaporated to give 500 mg of a
white powder. This substance was rechromatographed
on a column of CM-Sephadex, ammonium form ~Pharmacia
Fine Chemicals, Piscataway, New Jersey, USA), eluting
with 0.5 molar ammonium bicarbonate. The bed volume
was 3 cm by 50 cm; and 10 ml fractions were col-
lected. Fractions 65 to llO were combined andevaporated to give 250 mg of a whi~e solid. It was
taken up in dilute hydrochloric acid, then reevapor-
ated.
MS-1168
. ~
~2~17~
- 41 -
The residue was recrys-tallized from methanol to
give 90 mg (3% yield) of ~he hydrochloric acid salt
of (VI) as pale tan needles that did nOt melt beJow
300C
All~lysis: Calculated for Clolll~N5C102: C,43.88;
~-l, 5.89; N~ 25.59.
Found: C, 43.77; ~1, 5.88; N, 25.46.
In-frared A~ectrum (KCI): 1695 cm 1 an~
1655 cm~l (amide carbonyls).
8-[2-(7-~-galactosylcoumarin-3-carboxamide)propyl]-
theophylline ( VIl I) .
A reaction mixture was prepared containing 24 g
of potassium hydroxide~ 80 ml of water, 240 ml of
methanol and 20 g (0.035 mmol) of ethyl 7-~-galac-
tosylcoumarin-3-carboxylate [Burd et aZ~ CIin. Chem.
23:1402 (1977)]. The reaction was stirred at 50C
-for 15 hours. When cool 9 the methanol was removed
under reduced pressure. The concentrated aqueous
solution was acidified to pH 2.0 with concentrated
2() hydrochloric acid. The white precipitate was col-
lected, washed with cold water, and recrystallized
from hot water. The crystals were collected, washed
with acetone, and dried at 80C for 1 hour. This
gave 12 g of 7-~-galactosylcoumarin-3-carboxylic acid
as white crystalsg mp 250-255C.
A mixture of 1.45 g (0.004 mol) of 7-~-galactosyl-
coumarin-3-carboxylic acid! 404 mg (0.004 mol) of
triethylamine, and 40 ml of dry dimethyl formamide
(VMF) was cooled to -10C while s-tirring under argon.
3Q To this was added 546 mg (0.004 mol) of isobutyl
chloro-formate (Aldrich Chemical Co., Milwaukce~
Wisconsin) to ~orm the mixed anhydride (VII). len
nlinutes l~ter, an additional 404 mg of triethylamine
M~-116~
~o~
- ~2 -
and 949 mg (0.004 mol) of 8-(3-aminipropyl)theo-
phylline (VI) was ad~ed to the ~lask. ~\fter stirring
for 30 minutes at -10C, the reaction was allowed to
warm to room tempera~ure. It was combined Wit}l 10 g
of silica gel and the DMF removed under high vacuum.
The impregnated silica gel was placed atop a column
of 170 g of silica gel and ~he column eluted with
anhydrous ethanol and collecting 15 ml fractiolls.
Fractions 41 to 475 were combined and evaporated to
give 545 mg of a yellow solid. I~ was dissolved in
water, fil~ered, and concentrated to a 20 ml volume.
A small amount of precipitate formed and was dis-
carded. The filtrate was chromatographed on a 2.5 cm
by 57 cm column of Sephadex LH-20 gel ~Pharmacia Fine
Chemicals, Piscataway, New Jersey~, eluting with
water and collecting 15 ml fractions. Fractions 18
to 23 were combined9 evaporated, and residue recrystal-
lized :Erom water to give 55 mg ~2~ yield) of the
labeled conjugate ~VIlI) as a light yellow solid, mp
19(1-192C.
Analysis: Calculated for C26H29N5Oll: C, 53.15;
H, 4.98; N, 11.92.
Found: C, 52.65; H, 5.01; N, 11.80.
The abo~e-described synthesis of the ~-galac-
tosylcoumarin-theophylline conjugate (VIII), n = 3,
can be modified to yield labeled conjugates wherein n
= 2 through 6 by replacing the starting material 8-
~3-carboxypropyl)theophylline (V), n = 3, with the
appropriate 8-(~-carboxyalkyl)theophylline as fol-
lows:
n alkylene
2 ethylene
4 butylene
pentylene
3 r~ 6 hexylene
MS-1168
3'7~
- ~3 -
An~iserllm Prepa'ration
Antiserum was collected rom rabbits immunized
with a theophylline immunogen conjugate prepared as
described by Cook et aZ, ~es. ~o~m. ~hem. Path. Pharw
maco~. 13:497-505 ~1976~.
Element Preparation
Preparation o~ the analytical element was as
described in F,xample 1 with the exception that the
conjugate and antiserum used were those prepared as
described in this Example and that the conjugate was
dissolved in dimethylsuloxide ~DMSO) rather than
formate.
Final reagent contents per theophylline immuno-
assay element were as follows:
COMPONENTTHEOP~IYLLINE
Volume Antisera 10 ~I.
Conjugate ~-gal-umb-theophylline
Quantity 129.9 picomoles
Bufer ~bicine)2.0 micromoles
~-galactosidase .065 Units
DMSO 0.17 ~L
Anal`ytical Proce'dure
The procedure followed in per~orming the assays
reported by this Examp'le were identical with those
'5 (lescribed in Example 1.
MS-1168
,
. .
.:
., ~. .
:~2~t7~
- ~4 -
The concentration ranges assay were as follows:
RANGE THEOPHYLLINE
Therapeutic Range 10-20 ~g/ml
Dose Response
Range Checked 1-4.0 ~g/ml
The dose response range checked includes the thera-
peutic range after a 1:40 clilution.
Results
The data obtained by the above-described pro-
cedure is graphically illustrated by Figure 6. The
ordi-nate units are expressed in terms of nanoampers
tnamps). A nanoampere is one billionth of an ampere.
Conclusion
The-resultant data show that integral analytical
elements, prepared according to the invention provide
qwantitatively detectable signals which are responsive
to the concentration ranges o the theophylline pre-
sent. Increasing concentrations of theophylline
results in a drug dependent increase in fluorescence
of the respective analytical elements. The techni-
ques used in the experiment described have made it
possible for all components to be included in a
single solution which is incorporated with a carrier
to form a single element.
MS-1168
~' `. ' ~'
~,:
'7S
- 45 -
E~am~Ze lV ~ Carbamaze~ne Assay
Carbamazepine ~5l-l--dibenz[b~f]azepine-5-carboximde7
cf. The Mer~k Inde~, 9th ed., p. 226 (1976)~, sold
under various trademarks including Tegretol, is an
anti-convulsant drug useful in the management of
epilepsy. The therapeutic range of serum concen-
tration in most patients lies between 4 and 12 ~g/ml
whereas toxic signs may appear at blood levels over
12 ~g/ml.
Conjugate Preparation
~ -galactosyl-umbelliferone-labeled carbamazepine
conjugates are prepared according to the reaction
scheme shown Figure 7 in the drawings. This syn-
thetic route is exemplified by the following method
of preparing N-[4-(7-g-galactosylcoumarin-3-carboxa-
mido)butyl]aminocarbonyl-5H-dibenz[b,f]azepine (XII),
n = 4.
N-(4-Aminobutyl)aminocarbonyl-5H-dibenz[b,f]azepine ~x)
-
Phosgene gas was bubbled into a room temperature
suspension of 14.1 g (0.073) o-f 5H-dibenz[b,f3azepine
(Aldrich Chemical Co., Milwaukee, Wisconsin) in 180
ml of dry toluene until 15 g was absorbed. The warm
mixture was stirred for 2 hours, heated at reflux for
2 hours, then stirred at room temperature overnight.
The yellow so].ution, now containing N-chlorocarbonyl-
5H-dibenz[b,f]azepine (IX), was concentrated by
boiling to about 100 ml volume. It was added drop-
wise over 1 hour to a solution at room temperature of
MS-1168
..
7~
- 46 -
26 g (0.29 mol) of 1,4-diaminobutane in 250 ml of
toluene. A white crystal]ine solid began to pre-
cipitate immediately. After the acldition was com-
plete, the resulting slurry was stirred at reflux for
3 hours. It was then cooled, filtered, and the
precipi~ate washed with toluene. The filtrate was
evaporated and excess butane diamine was removed by
heating to 100C at 0.2 mm. The residual oil was
taken up in dilute hydrochloric acid and some in-
soluble material filtsred off. The solution was made
basic to pH 9.5 with sodium carbonate and extracted
with chloroform. Evaporation of this extract gave a
glass that solidified when triturated with ether.
This gave 15.8 g (70% yield) of the amine (x), as a
solid~ mp 114-116C.
Analysis: Calculated for ClgH21N3O; C, 74O24;
H, 6.89; N, 13.67.
Found: C, 73.92; H, 6.71; N, 13.64.
Infrared Spectrum (KCl); 1655 cm 1
(amide carbonyl).
N-[4-(7-3-Galactosylcoumarin-3-carboxamido)butyl]-
aminocarbonyl-5H-dibenz[b,f~azepine (XII ) .
A mixture of 24 g of potassium hydroxide, 80 ml
of water~ 240 ml o-f methanol, and 20 g (0.035 mol) of
ethyl 7-~-galactosylcoumarin-3-carboxylate [Burd et
- aZ, C~in. Chem. ] was prepared. The methanol was
removed under reduced pressure. The concentrated
aqueous solution was acidified to pH 2.6 with con-
centrated hydrochloric acid. The white precipitate
was collected, washed with cold water, and recry-
stallized from hot water. The crystals were col-
lected, washed with acetone, and dried at 80C for 1
MS~ )8
7~
- 47 -
hour. This gave 12 g (54% yield) of 7-~-galactosyl-
coumarin-3-carboxylic acid as white crystals, mp 250-
255C.
A mixture of 1.02 g (5 mmol) of dicyclohexylcar-
bodiimide~ 575 mg ~5 mmol) o N-hydroxysuccinimide,
and 50 ml of dry dimethylformamide (DMF) was stirred
at room ~emperature under argon for 30 minutes. The
clear, colorless solution was cooled to -5 and 1.835
g (5 mmol) of 7-~-galactosylcourmarin-3-carboxylic
acid was added. The reaction was allowed to warm to
room temperature and stirred ~or 2 hours. The mix-
ture was then cooled in an ice ba-th and the preci-
pitate of dicyclohexyl urea removed by filtration
under argon. The filtrate, now containing the N-
hydroxysuccinimide ester (XI), was combined with1.54 g (5 mmol) of N-(4-aminobutyl)aminocarbonyl-5H-
dibenz[b,f]azepine (X) dissolved in 5 ml of DMF.
The reaction was stirred overnight at room tempera-
ture. The solvent was removed at 50C/12 mm on the
rotary evaporator and the residue triturated with
dilute aqueous sodium bicarbonate solution. The
insoluble material was chromatographed on 100 g of
silica gel (E. Merck Co., Darmstadt, West Germany)
eluting with a gradient of 2 L of ethyl acetate ~o 2
L of ethanol and 20 ml fractions were collected.
Fractions 190 to 250 were combined, evaporatcd, and
the residue recrystallized twice from ethanol. This
gave 1.0 g (30% yield~ of the labeled conjugate (XII)
as a white powder, mp 150-160C (decomposed).
Anaylsis: Calculated for C35ll35N3Olo: C, 63.95:
H, 5.35~ N, 6.39.
Found: C, 63.55; H, 5.77~ N, 6.14.
Mass Spectrum (field desorption): m/e
6S8, [P ~ 1].
Optical Rotation: [~]D = -46.84 (c
1.0, MeOH?
* ~ * * *
MS-ll fl ~
s
- 48 -
The above-described synthesis of the ~-galactosyl-
coumarin-carbamazepine conjugate (XII), ~ = 4, can be
modified to yield labeled conjugates wherein n = 2
through 6 by replacing the starting material 1,4-
diaminobutane with the appropriate ~,w-diaminoal]cane
as follows:
n a, w- diaminoalkane
2 éthylenediamine
3 1,3-diaminopropane
1,5-diaminopentane
6 1,6-diaminohexane
Antiserum Preparation
Antiserum was obtained by immunization of rab-
bits with carbamazepine-bovine serum albumin imlnuno-
gen conjugate.
E'lement ~
Preparation of the analytical element was asdescribed in Example 1 with the exception that the
conjugate and antiserum used were tllose prepared as
described in this Example and that the conjugate was
dissolved in DMSO.
Final reagent contents per carbam~zepine immuno-
assay element were as follows:
MS-1168
,:
- 49 -
COMPONENT CARBAMAZEPINF.
-- (C~3Z)
Volume Antisera 10 ~L
Conjuga~e ~-gal-umb-CBZ
Quantity 112.3 picomoles
Buffer ~bicine) 2.0 micromoles
~-galactosidase .065 Uni-ts
DMSO 0.17 ~L
Analytical Procedure
The procedure followed in performing the assays
reported by this Example were identical with those
described iTl Example 1.
The concentration ranges assayed were as follows:
RANGE CARBAMAZEPINE
_
Therapeutic Range 4-12 ~g/ml
Dose Response Range 0-0.4 ~g/ml
Checked
The dose response range checked includes the thera-
peutic range after a 1:50 dilution.
Results
The data obtained by the above--described procedure
is graphically illustrated by Pigure 8. The ordinate
units are expressed in terms of elec~rical output.
MS-1168
'-7~
- 50 -
onclusion
The resul-tant data show that integral analytical
elements, prepared acçordi.ng to the invention, pro-
vide quantitatively detectable signals which are
responsive to the concentra~ion ranges of the car-
bamazepine present. Increasing concentrations o-f
carbamazepine result in a drug dependent increase in
fluorescence of the respective analytical elements.
The techniques used in the experiment described have
made it possible for all components to be combined in
a single solution which is incorporated with a car-
rier to form a single element.
MS-1168
